ALK and non-small cell lung carcinoma: Cemiplimab is an FDA-approved monoclonal antibody targeting PD-1 for the first-line treatment of patients with locally advanced or metastatic, PD-L1-high nonsquamous and squamous NSCLC harboring no EGFR/ALK/ROS1 alterations.